Latest Breaking News On - இரண்டாவது முக்கிய கட்டம் - Page 1 : comparemela.com

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ACHL) - The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ACHL) - The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesDynavax cpPeter thomasChristopher morabitoJames geraghtyBrickell biotech incAerovate therapeutics incUs army medical research developmentAddex therapeutics ltdAngion biomedica corpVaccine allianceGuardant health incPanbela therapeutics incCantor fitzgeraldGuardant health discloses institutional ownershipKiromic biopharma inc

Recent Otezla Growth: A Result of the Amgen Acquisition or Benefiting from the Pandemic?

Share this article Share this article EXTON, Pa., Feb. 10, 2021 /PRNewswire/ Despite the potential for setbacks brought forth by the COVID-19 pandemic, Amgen recently reported strong year-over-year growth for their newly acquired psoriasis (PSO) and psoriatic arthritis (PsA) agent, Otezla. 1 In late 2019, the brand was sold to Amgen in order to clear the path for Bristol-Myers Squibb s acquisition of Celgene, considering future regulatory conflicts with BMS pipeline psoriasis drug, deucravacitinib, an oral TYK2 inhibitor anticipated to be in direct competition with Otezla. Amgen s purchase of Otezla strengthens the company s long-standing immunology portfolio, including TNF inhibitor, Enbrel, which has been approved in RA for over two decades and also holds a dual PSO/PsA indication. However, according to ongoing feedback collected from US dermatologists and rheumatologists included in Spherix s

Novarti cosentyxEli lilly taltzBob bradwayKristen hennEli lillyBristol myers squibbAbbvie skyriziDermatologic siliqJanssen tremfyaOur servicesAmgen incBusiness developmentRealtime dynamixOrtho dermatologic siliqSun dermatologySpecial topix